RxDoctor Payments Data

Jeanette Figueroa, MD

Family Medicine · Hamburg, NYNPI 1710972245

Payments from drug & device makers

$14,706in general payments, 2019–2025

Across 331 payments — averaging $44.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pentax Of America, Inc.$7K
  • AstraZeneca$1K
  • AbbVie$875
  • Lilly USA, LLC$854
  • Novo Nordisk$653
  • GSK$648
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,14349%
  • Education$941%
  • Other$7,46851%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,706 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$25,736
Medicare patients
130
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$98,412
EliquisApixaban55$67,105
TrulicityDulaglutide35$65,606
JardianceEmpagliflozin34$58,368
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$38,582
ProliaDenosumab15$25,924
MounjaroTirzepatide24$24,149
XareltoRivaroxaban14$21,591
MyrbetriqMirabegron16$10,964
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$9,808
Breo ElliptaFluticasone/Vilanterol18$7,317
SymbicortBudesonide/Formoterol Fumarate14$6,581
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$4,634
Atorvastatin Calcium288$3,602
Levothyroxine Sodium210$3,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$653$98,41274 claims
Lilly USA, LLCTrulicity, Mounjaro$854$89,75659 claims
PfizerEliquis$254$67,10555 claims
Boehringer IngelheimJardiance$246$58,36834 claims
GSKTrelegy Ellipta, Breo Ellipta$648$45,90062 claims
AmgenProlia$408$25,92415 claims
Johnson & JohnsonXarelto$34$21,59114 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,330$16,38931 claims
Astellas Pharma US IncMyrbetriq$237$10,96416 claims
AbbVieSynthroid$875$2,01929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Hamburg

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →